TheraRadar
← Back
Data updated: Mar 29, 2026

EPIZYME INC

OncologyGastroenterology
Pharma

EPIZYME INC is a pharmaceutical company focused on Oncology, Gastroenterology. Key products include TAZVERIK.

2020
Since
1
Drugs
-
Trials
1
Approved (2yr)

Key Drugs

TAZVERIK
tazemetostat hydrobromide
Oncology
EZH1 2 indications · 2020

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

TAZVERIK 2024-08-13
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 96%
1 drugs Phase 3: 1 Phase 2: 3 Phase 1: 9
Gastroenterology 4%
0 drugs Phase 1: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Gastroenterology
Takeda big-pharma
Oncology, Gastroenterology
Gilead Sciences biotech
Oncology, Gastroenterology
ASTELLAS specialty
Oncology, Gastroenterology